AUG 7·SEC EDGARLow
Atay Oguzhan sold $2.3M of BLLN
Atay Oguzhan (Chairman and CEO) sold 15,539 shares of BillionToOne, Inc. (BLLN) at $150.03 ($2.33M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · DIAGNOSTICS & RESEARCH
$BLLN
BillionToOne, Inc.
Price · $BLLNvia TradingView
AI sentiment · 7d2 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 1
Top stories · $BLLNMore →
AUG 6·benzinga.com
BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)
BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.
AUG 6·SEC EDGAR
Atay Oguzhan sold $1.7M of BLLN (indirect holdings)
Atay Oguzhan (Chairman and CEO) sold 12,500 indirectly-held shares of BillionToOne, Inc. (BLLN) at $137.37 ($1.72M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
BLLN sentiment & insider activity
Over the past 7 days, alphai's AI scored 2 news stories mentioning BLLN (BillionToOne, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent BLLN coverage spans insider activity, earnings and sector analysis.
In the last 30 days, BLLN insiders filed 51 SEC Form 4 transactions — no purchases and 51 sales ($16.5M). The most active reporter was Atay Oguzhan, Chairman and CEO, with 28 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
What's driving BLLN
This is a routine, pre-arranged insider sale disclosure; it may slightly affect sentiment but does not signal a new operational or financial change.
After-hours selloff suggests investors discounted the Q2 print despite revenue growth and profitability, likely reacting to margins, test growth quality, or forward expectations not captured by guidance range.
This is an insider open-market sale under a pre-arranged 10b5-1 plan, which is typically lower-signal than discretionary selling but can still affect near-term sentiment.
This is a routine insider open-market sale under a 10b5-1 plan, with limited direct signal on near-term fundamentals.
The 8-K provides fresh quarterly financials plus unchanged full-year revenue guidance, supporting a near-term valuation read-through and positioning around upcoming commercial feature launches.
alphai scores every news story that mentions BLLN with an AI model for sentiment and relevance, and aggregates insider trades from BillionToOne, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $BLLN
Score
Atay Oguzhan sold $2.3M of BLLN
Atay Oguzhan (Chairman and CEO) sold 15,539 shares of BillionToOne, Inc. (BLLN) at $150.03 ($2.33M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
2 min read
BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)
BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.
3 min readAtay Oguzhan sold $1.7M of BLLN (indirect holdings)
Atay Oguzhan (Chairman and CEO) sold 12,500 indirectly-held shares of BillionToOne, Inc. (BLLN) at $137.37 ($1.72M total) across 2 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
2 min readAtay Oguzhan sold $4.5M of BLLN
Atay Oguzhan (Chairman and CEO) sold 32,500 shares of BillionToOne, Inc. (BLLN) at an average of $136.95 ($133.00–$139.21, $4.45M total) across 21 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
2 min readBillionToOne, Inc. (BLLN): Results of Operations and Financial Condition
BillionToOne, Inc. (BLLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a991blln-earningspressrele.htm EX-99.1 Document BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance MENLO PARK, CA, August 5, 2026 - BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to cr
7 min readSakakibara Shan Riku sold $561K of BLLN
Sakakibara Shan Riku (Chief Product Officer) sold 4,000 shares of BillionToOne, Inc. (BLLN) at $140.21 ($0.56M total) on 2026-07-31 under a Rule 10b5-1 trading plan.
1 min readTop Specialty Labs and Diagnostics Stocks, According to BTIG By Investing.com
Investing.com reports BTIG analyst Mark Massaro previewed seven specialty labs and diagnostics stocks as valuations rise. BTIG rates Guardant Health (GH) Buy, $190 target; Natera (NTRA) Buy, $290; BillionToOne (BLLN) Buy, $142; GeneDx (WGS) Buy, $90; Adaptive Biotechnologies (ADPT) Buy, $24; Tempus AI (TEM) Buy, $80; Caris (CAI) Buy, $32, with Q2 expectations and volume or catalyst updates.
5 min readJohnson Nancy JoAnn sold $1.8M of BLLN
Johnson Nancy JoAnn (See Remarks) sold 14,199 shares of BillionToOne, Inc. (BLLN) at an average of $128.29 ($126.98–$129.78, $1.82M total) across 4 trades on 2026-07-16 under a Rule 10b5-1 trading plan.
1 min readten Bosch John Roderick sold $533K of BLLN
ten Bosch John Roderick (SVP of Laboratory Operations) sold 4,251 shares of BillionToOne, Inc. (BLLN) at $125.46 ($0.53M total) across 3 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
2 min readTsao David sold $2.5M of BLLN
Tsao David (Chief Technology Officer) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $124.88 ($122.84–$126.90, $2.50M total) across 10 trades on 2026-07-13 under a Rule 10b5-1 trading plan.
2 min read